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Abstract 
Conventional methodologies to control vector borne diseases with chemical pesticides are 
often  associated  with  environmental  toxicity,  adverse  effects  on  human  health  and  the 
emergence of insect resistance.  In the paratransgenic strategy, symbiotic or commensal 
microbes of host insects are transformed to express gene products that interfere with 
pathogen transmission.  These genetically altered microbes are re-introduced back to the 
insect where expression of the engineered molecules decreases the host’s ability to transmit 
the pathogen.  We have successfully utilized this strategy to reduce carriage rates of Trypa-
nosoma cruzi, the causative agent of Chagas disease, in the triatomine bug, Rhodnius prolixus, 
and are currently developing this methodology to control the transmission of Leishmania 
donovani by the sand fly Phlebotomus argentipes. Several effector molecules, including antimi-
crobial peptides and highly specific single chain antibodies, are currently being explored for 
their anti-parasite activities in these two systems.  In preparation for eventual field use, we are 
actively engaged in risk assessment studies addressing the issue of horizontal gene transfer 
from the modified bacteria to environmental microbes. 
Key words: Paratransgenesis, Chagas disease, triatomine bugs, visceral leishmaniasis, sand flies, 
microbiology, risk assessment, horizontal gene transfer 
Introduction 
Paratransgenesis is a “Trojan Horse” approach to 
control of disease transmission. In this strategy, bac-
terial flora native to disease-transmitting vectors are 
isolated and genetically transformed in vitro to export 
molecules that interfere with pathogen transmission. 
The  genetically  altered  symbionts  are  then 
re-introduced into the host vector where expression of 
engineered  molecules  affects  the  host’s  ability  to 
transmit the pathogen, i.e. its vector competence. This 
approach attempts to decrease pathogen transmission 
without  adverse  effects  on  vectors  themselves.  Fur-
ther, it employs, as a gene delivery mechanism, bac-
terial flora native to the host vector.  
 There are several requirements for such an ap-
proach to work[1]: (a) a population of symbiotic bac-
teria  must  exist  within  a  given  disease-transmitting 
vector (b) symbiotic bacteria should be specific to a 
given vector (c) bacterial symbionts should be ame-
nable to culture and genetic manipulation (d) genet-
ically altered symbionts should remain stable (e) fit-
ness of the genetically altered symbionts to re-infect 
host vectors should not be compromised, nor should 
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their  normal  symbiotic  functions  be  altered  (f) 
transgene products released from the genetically al-
tered symbionts should interact with the target path-
ogen(s) and (g) a method must exist for dispersal of 
the genetically altered symbionts amongst naturally 
occurring  populations  of  vectors  with  minimal 
non-target spread of foreign genes to environmental 
bacteria and other arthropods. 
Our  laboratory  had  pioneered  the  paratrans-
genic  approach  to  control  Trypanosoma  cruzi  trans-
mission by triatomine vectors of Chagas disease[2, 3].  
We have since applied this technique to a number of 
other  arthropod  systems,  including  sand 
fly-transmitted  leishmaniasis[4]  and  sharpshoot-
er-mediated  Pierce’s  disease  of  grapes[5].    We  are 
further developing a modification of this procedure to 
control diseases in shrimp mariculture[6].  In this re-
view, we will describe how this approach is utilized to 
impart passive immunity to arthropod vectors – tria-
tomine bugs and sand flies – to render them incom-
petent to parasitic infections.  
Chagas disease 
Chagas  disease  is  caused  by  the  protozoan 
Trypanosoma cruzi  and  is  transmitted  to  humans  by 
blood-sucking  triatomine  bugs.  These  bugs  infest 
thatch  and  adobe  of  poorly  constructed  homes  and 
transmit  the  parasite  to  humans  via  fecal  droplets 
deposited following a bloodmeal.  This human para-
sitic  disease  is  endemic  throughout  much  of  rural 
Mexico as well as Central and South America. In re-
cent years, human migration from these regions of the 
world has significantly changed the epidemiology of 
this disease.  Today, there are a significant number of 
people  infected  with  T.  cruzi  in  the  United  States 
(>300,000), Canada (>5,500), Europe and the Western 
Pacific  (>80,000),  Japan  (>3,000),  and  Australia 
(>1,500)[7-9]. Of the 8 –11 million people infected with 
T. cruzi globally, approximately 50,000 will die each 
year[10].  Chagas  disease  accounts  for  the  loss  of 
500,000 disability-adjusted life-years annually, second 
only to malaria and leishmaniasis in the global cal-
culus of vector borne diseases.   
There are three successive stages of Chagas dis-
ease. The acute stage - characterized by generalized 
malaise, fever, lymphadenopathy, hepatosplenomeg-
aly - occurs shortly after infection and is minimally 
symptomatic  for  4  to  8  weeks.  The  indeterminate 
phase can last between 10 to 20 years and is charac-
terized by paucity of clinical manifestations but active 
replication of T. cruzi and periodic release of blood-
stream  forms  of  the  parasite  into  the  circulation. 
Decades  following  the  primary  infection,  between 
10-30%  of  infected  individuals  progress  to  chronic 
Chagas disease. Patients develop irreversible lesions 
of  the  autonomous  nervous  system  in  the  heart, 
esophagus,  colon  and  the  peripheral  nervous  sys-
tem[11, 12].  The chronic phase of Chagas disease is 
incurable  and  is  associated  with,  on  average,  a  ten 
year  shortening  of  life  span.  Gastrointestinal  mani-
festations  of  chronic  Chagas  disease  are  geograph-
ically restricted[13] and play a lesser role in the overall 
disease burden of Chagas disease.  Progressive heart 
disease,  a  hallmark  of  chronic  Chagas  disease,  is  a 
leading  public  health  concern  throughout  much  of 
Central and South America[14].  
 In the absence of vaccines and drug therapies, 
control of Chagas disease relies largely on measures 
aimed  at  vector  eradication.  Though  screening  of 
blood banks to reduce transfusion-associated Chagas 
disease is ongoing, public health measures aimed at 
interrupting  vector  transmission  to  humans  in  en-
demic  regions  have  the  potential  to  eliminate  this 
devastating  disease.  Several  large-scale  insecti-
cide-based  efforts  have  been  undertaken  with  con-
siderable success to date. The Southern Cone Initia-
tive, a joint agreement between the governments of 
Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay 
and  Peru,  was  launched  in  1991  to  control  Chagas 
disease by the elimination of the main vector, Triatoma 
infestans.  In  some  Southern  Cone  nations,  such  as 
Brazil, Uruguay and Chile, results have been dramatic 
and new cases of Chagas disease have been virtually 
eliminated[15,  16].  However,  several  factors  raise 
concern about the re-emergence of Chagas disease in 
the  Southern  Cone.  Reduced  effectiveness  of  pyre-
throids  in  peridomestic  habitats  had  led  to  the  in-
complete elimination of T. infestans in several South-
ern Cone countries[17-19].  Further, several Triatom-
ine  populations  have  been  documented  to  develop 
resistance to a variety of insecticides in Chagas dis-
ease  endemic  area[20].  For  these  reasons,  alternate 
methods aimed at controlling Chagas disease trans-
mission must be explored. 
Paratransgenic control of transmission of T. 
cruzi 
The  symbiotic  associations  between  triatomine 
vectors, specifically T. infestans and Rhodnius prolixus, 
and  nocardiform  actinomycetes  is  well  character-
ized[21].  Descriptions  of  nocardia-like  bacteria  in 
colony  populations  of  T.  infestans  date  back  to  the 
mid-1900’s[22]. These bacteria are thought to aid in 
the processing of B complex vitamins in the restricted 
blood diets of the host and are essential to the survival 
of the triatomine. The widespread carriage of nocar-
diform  actinomycetes  by  several  triatomine  species 
and the amenability of these bacteria to genetic ma-Int. J. Biol. Sci. 2011, 7 
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nipulation are the cornerstones of the paratransgenic 
strategies aimed at interrupting vectorial transmission 
of Trypanosoma cruzi.   
The  soil-associated  nocardiform  actinomycete 
Rhodococcus rhodnii resides extracellularly in the gut 
lumen of R. prolixus in close proximity to T. cruzi.  This 
microbe  is  transmitted  effectively  from  adult  tria-
tomine  bugs  to  their  progeny  through  coprophagy, 
the ingestion of fecal material from other bugs. The 
vital role of R. rhodnii in the growth and development 
of R. prolixus has been demonstrated repeatedly under 
laboratory  conditions.  R.  prolixus  nymphs  that  lack 
gut-associated symbionts (aposymbiotic) do not reach 
the  sexually  mature  adult  stage,  and  most  will  die 
after the second developmental molt. Introduction of 
the bacteria to first or second instar nymphs permits 
normal  growth  and  maturation.  In  1992,  we  trans-
formed R. rhodnii with pRr1.1, a shuttle plasmid con-
taining  a  gene  encoding  resistance  to  the  antibiotic 
thiostrepton,  to  support  the  hypothesis  that  a 
transgene-carrying symbiont could be introduced into 
R. prolixus.  We showed that the modified symbiont is 
maintained through the insect’s development without 
adverse effects on insect survival and fitness[23].  We 
have since developed a number of anti-trypanosomal 
molecules  – antimicrobial  peptides (AMP’s), recom-
binant endoglucanases that disrupt the surface of the 
parasite and functional transmission-blocking single 
chain antibodies - for expression in triatomine vectors.  
In a seminal study, we re-populated aposymbi-
otic R. prolixus nymphs with R. rhodnii transformed to 
express the AMP cecropin A[3]. These paratransgenic 
insects were then allowed to engorge on T. cruzi-laden 
human blood. At the end of the trial, 65% of the in-
sects  examined  had  complete  clearance  of  viable  T. 
cruzi.  The remaining 35% of the bugs had substan-
tially  reduced  numbers  of  parasites,  demonstrating 
that the in vivo expression of an AMP from a genet-
ically  modified  symbiont  can  significantly  reduce 
carriage of the infectious parasite from the host vector.  
AMP’s are a class of peptides that are recognized as 
important components of innate cell defense mecha-
nisms[24, 25].  They are produced in insects, plants, 
and animals, are present on a variety of cellular sur-
faces, and vary considerably in primary and second-
ary  structure[26].  AMP’s  are  amphipathic,  highly 
basic  molecules  that  can  discriminate  between  host 
and  bacterial  membranes  by  charge  and  composi-
tion[26].  While most AMP’s disrupt membranes of 
non-host cells, other modes of actions, including in-
terfering  with  host  metabolism  and  targeting  cyto-
plasmic components have been reported[25, 27, 28].  
We recently reported on the in vitro activities of sev-
eral other AMP’s against  T. cruzi.  We showed that 
apidaecin, magainin and mellittin had toxicity profiles 
that may be applicable to the Chagas paratransgenic 
system, killing T. cruzi at concentrations lower than 10 
uM and requiring greater than 100 uM to show any 
effect  on  R.  rhodnii[29].    Further,  when  used  in 
pair-wise combinations, these anti-microbial peptides 
resulted in much improved T. cruzi killing efficiency.  
For example, when used alone, apidaecin kills T. cruzi 
at  10  uM,  but  when  used  in  combination  with  ce-
cropin,  melittin  or  magainin,  the  concentration  re-
quired for killing is decrease by 10-fold (Figure 1).  We 
have now generated strains of R. rhodnii that produce 
four  different  AMP’s;  cecropin,  apidaecin,  melittin 
and magainin.  Lysates from these cells are biologi-
cally active against T. cruzi (Fieck et al, in prep).  Work 
is  currently  in  progress  to  introduce  these  trans-
formants either individually, or in combination, into 
aposymbiotic  triatomine  nymphs.    Based  on  our  in 
vitro data (Fieck et al, in prep), we would expect close 
to 100% clearance of T. cruzi following challenge. 
A number of other anti-trypanosomal molecules 
are currently being assessed for expression in R. rhod-
nii. One such molecule is 1,3-glucanase. The surface 
of T. cruzi is covered by a thick coat of glycoconju-
gates, the major component of  which is a family of 
mucin-like  glycoproteins. These  glycoconjugates  are 
required by the parasites for attachment, and subse-
quent infection, in the hindgut of the triatomine vec-
tor[30]. In unpublished work, we had shown that Ar-
throbacter luteus lyticase, an endoglucanases complex 
consisting of 1,3-glucanase and alkaline proteases, is 
very efficient in lysing T. cruzi in vitro, and is non-toxic 
to R. prolixus. We recently inserted the cDNA encod-
ing Arthrobacter luteus -1,3-glucanase into pRrExpA, 
our  E.  coli/R.  rhodnii  shuttle  vector.    Recombinant 
-1,3-glucanse is biologically active, and clears T. cruzi 
at low concentrations (Jose et al, in prep), suggesting 
that it could potentially be used as another effector 
molecule  for  the  paratransgenic  control  of  Chagas 
disease.   
Competence of the triatomine vector to transmit 
T. cruzi depends in part on parasite maturation in the 
insect gut.  This maturation process, also known as 
metacyclogenesis or the transformation from nonin-
fective epimastigotes into metacyclic trypomastigotes, 
is dependent in part on interactions between surface 
epitopes of T. cruzi and the gut lumen of the triatom-
ine bug. These interactions could therefore be a po-
tential  target  for  paratransgenic  expression  of  anti-
body fragments.  Recombinant single chain antibodies 
(scFv) are fusion proteins containing the variable re-
gions of the heavy and light chains of immunoglobu-
lins. These regions are connected to one another with 
a short linker of about 10 amino acid residues.  De-Int. J. Biol. Sci. 2011, 7 
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spite the absence of the constant regions, these pro-
teins retain specificity to target antigens comparable 
to that of parent immunoglobulins.  Because of their 
small  size,  scFv’s  are  readily  produced  in  bacterial 
cultures. In previous work, we genetically modified R. 
rhodnii to produce a functional murine three-domain 
antibody  fragment  (rDB3)  that  binds 
progesterone[31].  The  scFv-producing  cells  were 
subsequently  fed  to  aposymbiotic  R.  prolixus.    We 
showed that the rDB3 antibody fragment was synthe-
sized and secreted into the insect gut lumen by the 
engineered  symbiont  in  a  stable  fashion  over  the 
6-month period of the study. We later repeated these 
studies via the successful transformation of a Coryne-
bacterium  symbiont  of  T.  infestans,  with  the  same 
shuttle  plasmid[32].    Recently,  we  reported  on  the 
design, assembly, production and characterization of 
two scFV’s that are tagged with intrinsic red fluores-
cent properties to the sialyl-Tn and sialyl-(le)a surface 
glycans  of  T.  cruzi[33].  The  monoclonal  antibodies 
B72.3 and CA19.9 bind to the above glycans, respec-
tively.  Using these monoclonals as a template, syn-
thetic DNA sequences of B72.3 and CA19.9 antibody 
variable domains in VH–VL orientation were gener-
ated.  Instead of a standard linker, a monomeric red 
fluorescent  protein  (mRFP)  from  Discosoma  was  in-
serted as a rigid linker between the VH and VL do-
mains, generating a novel and highly stable REDan-
tibody. The resulting recombinant fluorescent mole-
cules were demonstrated to specifically bind to fixed 
T. cruzi epimastigotes by confocal microscopy (Figure 
2).  The ability of these molecules to bind and inacti-
vate live parasites is currently being investigated.  We 
are also in the process of subcloning genes encoding 
these novel antibodies into our shuttle vector system 
for expression in R. rhodnii.   
 
 
Figure 1: Antimicrobial peptide kill curves for dual-combination treatments of T. cruzi liquid cultures.  Results averaged 
from triplicate samples in three separate experiments and displayed as the percent change in absorbance at 600 nm 
compared to untreated controls.  Figure is adapted from Fieck et al, Trypanosoma cruzi: synergistic cytotoxicity of multiple 
amphipathic anti-microial peptides to T. cruzi and potential bacterial hosts, Exp Parasitol, 2010, 125:342-347 
 Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
1338 
 
Figure 2: Confocal image of anti-sialy-Tn REDantibody targeting glycan structures on the surface of T. cruzi epimastigotes. 
Figure adapted from Markiv et al. Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods, 
2011, 364:40-49 
 
Though many triatomine vectors of T. cruzi exist, 
we have focused primarily on genetically modifying 
R. rhodnii, the symbiont of R. prolixus, for paratrans-
genic purposes.   As described earlier, the paratrans-
genic approach derives from the close symbiotic as-
sociation between bacteria and arthropod vector. In 
light of this, we had examined the specificity of sym-
bionts in several triatomine vectors.  A wide variety of 
bacterial genera, including Nocardia, Corynebacteria 
and Streptococci, were isolated from the midgut of T. 
infestans[34]. In previous studies, we had identified a 
novel Corynebacterium symbiont from laboratory col-
onies of T. infestans isolated from the Gran Chaco re-
gion of Argentina[32], and studied the role of nocar-
diform  actinomycetes  such  as  Rhodococci,  Nocardia 
spp,  Gordonia  spp,  Corynebacterium  spp  and  Tsuku-
murella [1-3, 31, 32] in a number of triatomine bugs, 
including T. dimidiata and T. sordida (Pennington and 
Durvasula, unpublished data). In all cases, we noted 
that absence of matched actinomycetes in the arthro-
pod resulted in growth arrest and death of nymphs.  
However, when introduced into the correct vector, the 
actinomycetes supported growth and sexual matura-
tion of these bugs.  These results suggest that symbi-
onts are indeed specific to their respective hosts, and 
would need to be first identified for each arthropod 
vector  of  T. cruzi  prior  to  initialization  of  the  para-
transgenic  strategy.  Once  modified,  the  genetically 
altered  symbiont  should  not  impair  vector  survival 
and  fecundity.  In  previous  studies,  we  had  shown 
that transformed R. rhodnii expressing either cecropin 
A or rDB3 resulted in no adverse effects on R. prolix-
us[3, 31].  The effects of apidaecin, mellitin, magainin 
and 1,3-glucanase-expressing R. rhodnii on R. prolixus 
are  currently  being  evaluated.    Finally,  since  scFv’s 
bind with high specificity to sites on the surface of T. 
cruzi, we expect that they will exert minimal toxicity 
to the vector. 
In preparation for field trials, we tested the effi-
cacy  of  a  simulated  triatomine-fecal  preparation, 
CRUZIGARD, consisting of an inert guar gum matrix 
dyed with India ink, as a method for delivery of en-
gineered  R.  rhodnii  to  colonies  of  R.  prolixus.    The 
CRUZIGARD  preparation  was  mixed  with  108 
CFU/ml of transformed  R. rhodnii, and used to im-
pregnate  cages  constructed  of  thatch  and  ado-
be-building  materials  from  the  Chagas-endemic  re-
gions  of  Guatemala  (Olopa)[35].  Adult  R.  prolixus 
from the Olopa district were placed in the cages and 
removed after eggs were laid. The experiments were 
conducted over a 9-month period. Genetically altered 
R. rhodnii were detected in approximately 50% of F1 
adults and comprised nearly 95% of the colony form-
ing units (CFU) in these bugs, providing evidence that 
CRUZIGARD  may  be  useful  as  a  gene  dispersal 
strategy  under  conditions  of  microbial  competition. 
To increase the likelihood of CRUZIGARD probing, 
we have on-going collaborations to develop triatom-
ine attractants and semiochemicals to supplement the 
current  CRUZIGARD  formulation.  The  addition  of 
these semiochemicals is further anticipated to increase 
the volume and duration of CRUZIGARD ingestion, 
and consequently, increase rates of vector inoculation 
with transformed symbiont.  
Demonstrating  vector  uptake  of  genetically  al-
tered symbionts and, ultimately, refractoriness to T. 
cruzi infection via CRUZIGARD does not suggest or 
substantiate a strategy for field delivery. A practical Int. J. Biol. Sci. 2011, 7 
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strategy  in  an  endemic  region  should  specify  the 
minimum  amount  of  transformed  symbionts  neces-
sary to prevent T. cruzi transmission to humans, and a 
method  of  CRUZIGARD  application  suitable  for 
at-risk  domiciles  in  the  endemic  region.  In  other 
on-going studies, we are working with collaborators 
to develop a theoretical framework to assess parame-
ters  such  as  minimum  effective  release  of 
CRUZIGARD  and  inoculation  of  target  triatomine 
population.  
We  further  realize  that  the  deployment  of  ge-
netically altered lines of bacteria to target field popu-
lations of triatomine bugs may have profound envi-
ronmental  consequences.  Horizontal  gene  transfer, 
uptake of foreign genes by non-target arthropods and 
microbial biodiversity may all be adversely affected 
by such a strategy.  We have developed a mathemat-
ical model predicting horizontal gene transfer (HGT) 
between  genetically  modified  R.  rhodnii  and  G.  ru-
bropertinctus.[36] The model treats HGT as a compo-
site event whose probability is determined by the joint 
probability of three independent events: gene transfer 
through  the  modalities  of  transformation,  transduc-
tion, and conjugation. Genes are represented in ma-
trices, with Monte Carlo method and Markov chain 
analysis used to simulate and evaluate environmental 
conditions. The model is intended as a risk assessment 
instrument  and  predicts  an  HGT  frequency  of  less 
than 1.14 x 10-16 per 100,000 generations at the 99% 
certainty  level.  This  predicted  transfer  frequency  is 
less than the estimated average mutation frequency in 
bacteria,  10-1  per  gene  per  1,000  generations.  This 
suggests even if HGT were to occur between R. rhodnii 
and G. rubropertinctus, the transgene would likely not 
persist in the recipient organism, and that the likeli-
hood of these unwanted events are low.  
The field release of engineered bacteria cannot 
occur until a rigorous risk assessment framework and 
regulatory apparatus are in place.  To inform the reg-
ulatory process, evaluation of the risks and benefits of 
the paratransgenic strategy are required.  Since such 
information will not readily be available through field 
release trials, we are working with several collabora-
tors  to  develop  a  framework  involving  rigorous 
mathematical modeling and simulations. Outputs of 
these  models  will  be  integral  to  informing  risk  as-
sessment and regulatory oversight of the paratrans-
genic program, and ultimately, to permit field trials of 
the paratransgenic strategy. 
Visceral leishmaniasis 
Leishmaniasis is a devastating neglected tropical 
disease caused by the obligate intracellular protozoa 
Leishmania donovani  in  India,  L. infantum  in  Europe, 
and L. chagasi in South America. Natural transmission 
occurs through the bite of an infected sand fly of the 
genus Phlebotomus (Old World) or Lutzomyia (New 
World).  This  disease  is  present  in  88  countries,  af-
fecting  approximately  two  million  people  per  year 
with a global prevalence of 12 million with 350 million 
people at risk for infection[37].    
Visceral  leishmaniasis  (VL)  is  among  the  most 
neglected  diseases  based  on  dearth  of  research  and 
notable lack of innovations in disease treatment and 
control.    It  is  by  far  the  most  devastating  form  of 
leishmaniasis, and is nearly 100% fatal if untreated. 
There  are  500,000  annual  new  cases  of  VL  in  the 
world, one-half of which occur in India.  Bihar, the 
most affected state in India, is home to nearly 90% of 
the new cases each year[38] followed by West Bengal 
and  Uttar  Pradesh.    Bihar  is  also  the  region  where 
approximately 95% of the mortality occurs among the 
reported VL cases in India[38]. The disease often pre-
sents as an indolent fever, malaise and wasting with 
co-existent splenomegaly, bone marrow involvement 
and hepatomegaly.  
Treatment of Visceral Leishmaniasis 
Treatment  of  leishmaniasis  varies  greatly  with 
the type of disease (cutaneous, mucosal, or visceral), 
Leishmania  species,  and  geographic  location.    Old 
World cutaneous disease often self-heals and as a re-
sult  requires  no  treatment.  New  World  cutaneous 
disease is less likely to self-resolve and because of the 
risk  of  development  of  mucosal  leishmaniasis  with 
Leishmania  braziliensis,  systemic  treatment  is  more 
commonly undertaken.  Treatment courses are often 
lengthy  and  cure  is  difficult  to  achieve  with  many 
cutaneous  and  mucocutaneous  forms.    Treatment 
modalities  for  cutaneous  leishmaniasis  range  from 
local  therapy  including  topical  treatments  and  in-
tralesional injections to systemic therapy with penta-
valent  antimonials,  amphotericin  B  or  miltefosine 
being used most commonly. 
The treatment of VL has changed substantially 
over the last decade.  Pentavalent antimonial drugs 
were the standard drug of choice until the emergence 
of  drug  non-responsiveness  in  highly  endemic  re-
gions such as Bihar, India[39]. Newer treatment mo-
dalities, while effective, pose practical limitations as 
the majority of patients suffering from VL are unable 
to  pay  for  costly  medications  and  hospitalization.  
Newer  therapies  include  multiple  formulations  of 
amphotericin B, paramomycin, and miltefosine.  Dose 
finding  studies  have  suggested  significant  efficacy 
with  even  a  single  dose  of  liposomal  amphotericin 
B[40],  however,  it  is  unlikely  that  this  single-dose 
regimen will be adopted into practice because of the Int. J. Biol. Sci. 2011, 7 
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risk of emergence of drug resistance.  Paramomycin, 
an  injectable  aminoglycoside  medication,  has  also 
been studied and found effective in clinical trials[41].  
Miltefosine, an oral agent with excellent skin penetra-
tion has proven successful in treatment of VL and has 
the  advantage  of  not  requiring  hospitalization  for 
administration[42].      Most  recently,  there  has  been 
evaluation of combinations of drugs for the treatment 
of  VL.    Combination  therapy  has  the  distinct  ad-
vantage of decreasing the risk of drug resistance, de-
creasing  the  side  effects  and  improving 
cost-effectiveness.    Regimens  found  to  be  effective 
include combination therapy with amphotericin B and 
miltefosine,  amphotericin  B  and  paramomycin  and 
miltefosine in combination with paramomycin[43]. 
In  the  absence  of  a  vaccine,  control  of  VL  has 
focused largely on vector eradication through pesti-
cide use.  Several large-scale control efforts have tar-
geted the elimination of domestic and peri-domestic 
populations of sand flies including Plebotomus argen-
tipes.  Initially, DDT spraying in India associated with 
the National Malaria Control Program in the 1960’s 
was very successful in reducing sand fly populations 
and cases of VL were nearly eliminated[44].  Howev-
er,  as  with  triatomine  vectors,  recent  studies  show 
certain  populations  of  sand  flies  gaining  insecticide 
resistance[45-47], resulting in growing concern about 
insecticide use that is cost prohibitive and responsible 
for  considerable  environmental  toxicity.    Further-
more, in many parts of Bihar and West Bengal, return 
of  peri-domestic  populations  of  sand  flies  has  been 
observed within one year of insecticide spraying[48].  
Paratransgenic control of leishmania 
transmission 
We are developing a paratransgenic strategy to 
control  transmission  of  L. donovani  by  P. argentipes.   
As in the case of Chagas disease control, we intend to 
prevent disease transmission by effectively providing 
the sand flies with passive immunity against the in-
vading  parasite.    We  chose  to  focus  our  paratrans-
genic efforts in Bihar, India where P. argentipes is the 
main vector for VL for several reasons. Though mul-
tiple studies have reported the difficulties in identi-
fying breeding sites of New World sandflies[49-52], 
there is substantial data attesting to identification of 
breeding sites of P. argentipes in eastern India[53-57].  
Ghosh  and  Bhattacharya[58]  described  P.  argentipes 
breeding sites in West Bengal and further described 
the population biology of this vector[59].  A study in 
Pondicherry, India delineated breeding sites of both 
P. argentipes and P. papatasi[60].  In VL-endemic re-
gions of Bihar State, Kesari et al.[61] were highly suc-
cessful in isolating sand fly larvae from soil samples 
of mixed dwellings and isolated cowsheds. The accu-
racy  in  identifying  these  sites  and  retrieving  larvae 
from the soil suggest that breeding sites of P. argenti-
pes in the endemic states of Bihar are characterized to 
some degree.  
To date, there are no known reports of any sym-
biotic bacteria associated with P. argentipes.  However, 
the gut microbiology of adult sandflies has been de-
scribed in the past[62]. In 2008, we detailed an exten-
sive analysis of the gut flora of P. argentipes trapped 
from four VL-endemic sites in Bihar, India, and con-
cluded that sand fly-microbial associations reflect the 
environment in which the sand flies reside[4]. In this 
survey, we identified 28 distinct gut microorganisms 
through 16S rDNA sequencing.  A number of these 
microbes,  including  Staphylococcus  spp.,  Escherichia 
coli,  and  Enterobacter,  are  all  human  pathogens, 
thereby precluding their use in a paratransgenic sys-
tem.  However, we also identified an abundance of 
several nonpathogenic soil bacteria that are used in 
industry including Bacillus megaterium, Brevibacterium 
linens, Bacillus subtilis, and Bacillus pumilis. Our goal is 
to use these “generally regarded as safe” microbes as 
delivery vehicles for anti-leishmanial compounds to 
sandflies.  
How would the paratransgenic strategy work in 
this vector? The life cycle of P. argentipes is short with 
a brief window of parasite development. Female sand 
flies  acquire  the  parasite  when  they  ingest  macro-
phages  infected  with  amastigotes  during  a  blood 
meal. The parasite matures within the alimentary tract 
of the sand fly as a promastigote form.  Four to five 
days after feeding, the promastigotes move forward 
to the esophagus and the salivary glands of the insect. 
When the sand fly subsequently takes a blood meal 
from the mammalian host, leishmania promastigotes 
are  transferred  to  the  host.  For  the  paratransgenic 
strategy to be successful in this system, the recombi-
nant  commensal  bacteria  should  preferably  persist 
within  the  sand  fly  gut  until  the  first  blood  meal. 
However,  an  anti-leishmania  recombinant  molecule 
may remain active in the sand fly gut in the absence of 
recombinant carrier (Figure 3). In our experience with 
paratransgenic triatomine bugs, recombinant cecropin 
A persisted for over 6 months in the gut lumen with 
biological activity [3]. Such an outcome would actu-
ally  be  viewed  as  highly  desirable  as  the  intended 
biological  effect  would  occur  with  reduced  risk  of 
unwanted spread of transgenic bacteria via activities 
of the adult flies[63].  
The acquisition of bacteria in P. argentipes has not 
been studied. However, the large number of soil and 
environmental bacteria isolated in our study suggests 
that  sand  flies  are  typically  colonized  by  microbes Int. J. Biol. Sci. 2011, 7 
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encountered  at  breeding  sites  or  during  sugar 
meals[4]. Our strategy is to deploy large concentra-
tions of transformed commensal bacteria at sand fly 
breeding  sites  to  selectively  colonize  the  emerging 
flies. We recently demonstrated the transstadial pas-
sage of GFP-B. subtilis transformants from 4th instar 
larvae to the emergent sand fly stage, thereby gener-
ating the first paratransgenic sand fly (Figure 4)[63].  
These  results  suggest  that  this  deployment  strategy 
can  be  a  viable  option  for  field  delivery  of  trans-
formed, non-pathogenic commensal bacteria to sand 
fly breeding sites.  We are currently evaluating several 
molecules,  including  AMP’s  and  scFv’s,  for  an-
ti-leishmania activity for ultimate field use.   
 
 
 
Figure 3: Paratransgenic strategy for control of leishmaniasis.  In this scheme, we propose to transform sand fly commensal 
bacteria to express anti-leishmania molecules (1), these genetically altered microbes will be introduced to sand fly breeding 
sites (2) where they will be consumed by sand fly larvae (3).  We have demonstrated that the genetically altered bacteria will 
be retained by the sand fly as it undergoes metamorphosis (4).  Expression of the anti-leishmania molecule in the gut of the 
emergent paratransgenic sand fly (5) would kill invading leishmania species, therefore rendering the sand fly refractory to 
infection (6), and thus transmission of the parasite. 
 
 
Figure 4: Whole mount of paratransgenic sand fly. A: shows the auto-fluorescence associated with the outer carapace and 
specific GFP fluorescence within the sand fly. B: shows GFP-specific fluorescence signal uncoupled from the background.  
These 4x-images were captures using a Nuance multispectral imaging system.  GFP-specific fluorescence is contained to the 
midgut chamber of the adult sand fly with no evidence of transfer to other regions of the insect. Figure is adapted from 
Hurwitz et al, The paratransgenic sand fly: a platform for control of Leishmania transmission. Parasit Vectors, 2011, 4:e82 Int. J. Biol. Sci. 2011, 7 
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Conclusions 
Despite great advances in public health world-
wide, insect-transmitted infectious diseases remain a 
leading cause of morbidity and mortality. Currently, 
the  best  methods  for  control  of  many  insect-borne 
diseases  involve  the  use  of  chemical  pesticides. 
Though such campaigns may, in the short term, yield 
spectacular  results,  environmental  toxicity  and  ad-
verse effects on human health limit the use of many 
chemical pesticides. Further, the emergence of insect 
resistance to a wide variety of insecticides has greatly 
undermined  their  efficacy.  Finally,  the  cost  of  re-
peated applications of pesticides is often prohibitive. 
We  describe  a  novel  method,  termed  paratransgen-
esis,  for  transmission  control  of  two  specific  vector 
borne  diseases,  Chagas  disease  and  visceral  leish-
maniasis, via expression of gene products in the insect 
vectors via transformed symbiotic or commensal mi-
crobes.   We show that the expression of AMP’s can 
significantly reduce carriage of T. cruzi in the hindgut 
of  triatomine  bugs.    We  have  recently  added  other 
molecules, such as endoglucanases and highly specific 
scFv’s, to our armamentarium of effector molecules 
for the paratransgenic control of T. cruzi transmission. 
Effector  molecules  that  may  be  effective  against 
leishmania are currently being studied.  
Unlike current arthropod eradication strategies 
with  insecticides,  the  paratransgenic  approach  does 
not  aim  to  eliminate  triatomine  bugs  or  sand  flies.  
Rather,  the  overarching  goal  is  to  modulate  the  in-
sect’s ability to transmit a parasite. Such an approach 
could  provide  valuable  tools  for  control  of  Chagas 
disease  and  VL  in  highly  endemic  regions  of  the 
world. 
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